{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:28:52Z","timestamp":1790224132383,"version":"4.1.0"},"reference-count":109,"publisher":"SAGE Publications","issue":"19-20","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Inherited and complex retinal degenerative diseases, such as retinitis pigmentosa, age-related macular degeneration, and glaucoma, represent a significant global burden of irreversible vision loss. Due to immense genetic and clinical heterogeneity and complex underlying mechanisms, these diseases still lack safe and effective disease-modifying treatments. This review summarizes the current landscape of gene therapeutic approaches to develop novel treatments for these blinding conditions. Specifically, we provide an update on several ongoing or completed clinical trials on gene-specific or gene-agnostic approaches, including recombinant adeno-associated viral vector-mediated delivery of the full gene or gene editing and antisense oligonucleotide components into the eye. We also discuss the initial clinical trial results of the use of the different approaches to ocular delivery, including subretinal, intravitreal, and suprachoroidal delivery. While long-term clinical trial data and refined clinical endpoints are essential to assess the efficacy, safety, and durability of these strategies, the data so far underscore the immense potential of gene therapy to revolutionize the management of retinal diseases in patients living with these debilitating conditions.<\/jats:p>","DOI":"10.1177\/10430342251379824","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:25:39Z","timestamp":1758201939000},"page":"1287-1300","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Update on Gene Therapy Clinical Trials for Eye Diseases"],"prefix":"10.1177","volume":"36","author":[{"given":"Nicolas","family":"Lonfat","sequence":"first","affiliation":[{"name":"Astellas Pharma Inc., Westborough, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moreno-Leon","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Westborough, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5207-0041","authenticated-orcid":false,"given":"Claudio","family":"Punzo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2454-1932","authenticated-orcid":false,"given":"Hemant","family":"Khanna","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Westborough, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-21-08936.1998"},{"key":"e_1_3_5_3_2","volume-title":"Principles of Neural Science","author":"Kandel ER","year":"2000","unstructured":"Kandel ER, , Schwartz JH, , Jessell TM, et al. Principles of Neural Science. McGraw-hill: New York: 2000."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.11.001"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30393-5"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20180030"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-20"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2012.07.003"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2017.00244"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.81"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(88)90242-5"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1357-4310(96)10037-x"},{"key":"e_1_3_5_13_2","first-page":"3","article-title":"Clinical investigation of retinitis pigmentosa","volume":"247","author":"Bird AC","year":"1987","unstructured":"Bird AC. Clinical investigation of retinitis pigmentosa. Prog Clin Biol Res, 1987; 247:3\u201320. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3317446","journal-title":"Prog Clin Biol Res"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0997-122a"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/83817"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308823"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1709211115"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017368"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S65732"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2006.05.002"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.027102"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319067"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.1032"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac226"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102925"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.05.009"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.159"},{"key":"e_1_3_5_28_2","unstructured":"Therapeutics B. Clinical Trials. 2025. Available from: https:\/\/www.beacontx.com\/clinical-trials\/"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.025"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000373"},{"key":"e_1_3_5_31_2","unstructured":"Andres-Mateos E. IND-enabling Studies to Support the Clinical Development of ATSN-201 a Subretinally Delivered Laterally Spreading Gene Replacement Therapy For X-linked Retinoschisis (XLRS). 2023. Available from: https:\/\/atsenatx.com\/wp-content\/uploads\/2023\/12\/ESGCT2023_INDXLRS-1.pdf"},{"key":"e_1_3_5_32_2","unstructured":"Therapeutics A. Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I\/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS). 2025. Available from: https:\/\/www.atsenatx.com\/press-release\/atsena-therapeutics-announces-positive-clinical-data-from-part-a-of-phase-i-ii-trial-evaluating-atsn-201-gene-therapy-to-treat-x-linked-retinoschis\/"},{"issue":"7","key":"e_1_3_5_33_2","first-page":"3925","article-title":"Novel gene therapy for XLRS: Initial findings from a clinical trial showing visual improvement","volume":"65","author":"Zhou W","year":"2024","unstructured":"Zhou W, , Shen Y. Novel gene therapy for XLRS: Initial findings from a clinical trial showing visual improvement. Investigative Ophthalmology & Visual Science, 2024; 65(7):3925.","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02520-3"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2024.017"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000385"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.3310\/WARA5730"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.06.006"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00558-y"},{"issue":"9","key":"e_1_3_5_40_2","first-page":"2712","article-title":"X-linked retinitis pigmentosa: Mutation spectrum of the RPGR and RP2 genes and correlation with visual function","volume":"41","author":"Sharon D","year":"2000","unstructured":"Sharon D, , Bruns GA, , McGee TL, et al. X-linked retinitis pigmentosa: Mutation spectrum of the RPGR and RP2 genes and correlation with visual function. Invest Ophthalmol Vis Sci, 2000; 41(9):2712\u20132721. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10937588","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1086\/340848"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-75402-4_64"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/78182"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1680635"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0763-1"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.6254"},{"key":"e_1_3_5_47_2","unstructured":"Caouette D. Biogen Announces Topline Results From Phase 2\/3 Gene Therapy Study for XLRP. 2021. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-topline-results-phase-23-gene-therapy-study"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100595"},{"key":"e_1_3_5_49_2","unstructured":"Pennesi ME. Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa. 2024. Available from: https:\/\/www.beacontx.com\/news-and-events\/beacon-therapeutics-announces-positive-12-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa\/"},{"key":"e_1_3_5_50_2","unstructured":"Yang P Lauer A Birch D et al. Subretinal Gene Therapy Drug AGTC-501 for XLinked Retinitis Pigmentosa (XLRP) Phase 1\/2 Multicenter Study (HORIZON): 36-Month Interim Results. 2024. Available from: https:\/\/www.beacontx.com\/wp-content\/uploads\/2024\/09\/2024-09-12-EURETINA-2024-HORIZON-36M-data-Paul-Yang-FINAL_website.pdf"},{"key":"e_1_3_5_51_2","unstructured":"Therapeutics B. Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for laru-zova (AGTC-501). 2024. Available from: https:\/\/www.beacontx.com\/news-and-events\/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501\/"},{"key":"e_1_3_5_52_2","unstructured":"Zimmermann C. 4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa. 2022. Available from: https:\/\/4dmt.gcs-web.com\/news-releases\/news-release-details\/4d-molecular-therapeutics-announces-fda-fast-track-designation"},{"key":"e_1_3_5_53_2","unstructured":"4D Molecular Therapeutics. 2023. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4d-molecular-therapeutics-announces-updates-clinical-pipeline"},{"key":"e_1_3_5_54_2","unstructured":"Therapeutics DM. 4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1\/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting. 2021. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4d-molecular-therapeutics-presents-interim-results-ongoing-4d"},{"key":"e_1_3_5_55_2","unstructured":"Masson G. 4DMT restructures pipeline extending cash runway through 2028. 2025. Available from: https:\/\/www.fiercebiotech.com\/biotech\/4dmt-tosses-2-programs-halts-funds-3-others-it-zeroes-latest-stage-clinical-gene-therapy"},{"key":"e_1_3_5_56_2","unstructured":"Summary of the Ninth Annual Retinal Cell & Gene Therapy Innovation Summit 2024. 2024. Available from: https:\/\/www.fightingblindness.org\/news\/innovation-summit-2024-summary-970"},{"key":"e_1_3_5_57_2","unstructured":"Therapeutics F. 2024. Available from: https:\/\/fronteratherapeutics.com\/news\/202.html"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.05.034"},{"key":"e_1_3_5_59_2","unstructured":"Incorvaia D. J&J gene therapy fails to improve visual navigation in late-stage rare eye disease trial. 2025. Available from: https:\/\/www.fiercebiotech.com\/biotech\/jj-gene-therapy-fails-improve-visual-navigation-late-stage-rare-eye-disease-trial"},{"key":"e_1_3_5_60_2","unstructured":"Therapeutics C. EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I\/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b. 2024. Available from: https:\/\/coavetx.com\/eyedna-therapeutics-announces-positive-24-month-data-presented-at-arvo-from-ongoing-phase-i-ii-trial-ofhora-pde6b-gene-therapy-in-patients-with-retinitis-pigmentosa-caused-by-bi-allelic-mutations-in-p\/"},{"key":"e_1_3_5_61_2","unstructured":"Therapeutics C. Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I\/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b. 2023. Available from: https:\/\/coavetx.com\/coave-therapeutics-announces-positive-12-months-data-from-ongoing-phase-i-ii-clinical-trial-of-ctx-pde6b-in-patients-with-retinitis-pigmentosa-caused-by-bi-allelic-mutations-in-pde6b\/"},{"key":"e_1_3_5_62_2","unstructured":"Blindness FF. Retinitis Pigmentosa Research Advances. 2025. Available from: https:\/\/www.fightingblindness.org\/news\/retinitis-pigmentosa-research-advances-899#:\u223c:text=Vision%20improvements%20in%20the%20trial corrected%20visual%20acuity%20(BCVA)"},{"issue":"8","key":"e_1_3_5_63_2","first-page":"782","article-title":"Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A-associated Retinitis pigmentosa","volume":"64","author":"Reichel FFL","year":"2023","unstructured":"Reichel FFL, , Michalakis S, , Fischer DM, et al. Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A-associated Retinitis pigmentosa. Investigative Ophthalmology & Visual Science, 2023; 64(8):782.","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.08.018"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51575-4"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102311"},{"key":"e_1_3_5_67_2","unstructured":"SpliceBio. U.S. FDA IND Clearance of SB-007 to Commence Phase 1\/2 Clinical Study in Patients with Stargardt Disease. 2024. Available from: https:\/\/splice.bio\/splicebio-announces-u-s-fda-ind-clearance-of-sb-007-to-commence-phase-1-2-clinical-study-in-patients-with-stargardt-disease\/"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2023.017"},{"key":"e_1_3_5_69_2","unstructured":"Vector G. West China Hospital completed the world\u2019s first gene therapy for Stargardt disease type 1 patient. 2024. Available from: https:\/\/www.jwksw.com\/newsinfo\/6723624.html"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"e_1_3_5_71_2","unstructured":"Euretina. 4-Year interim results of the PERCEIVE Study: Long term real-world safety and effectiveness of voretigene neparvovec. 2024. Available from: https:\/\/abstracts.euretina.org\/2024\/ca24-2078-2563\/r\/recOqcbzi4h1On3H8"},{"key":"e_1_3_5_72_2","unstructured":"Euretina. Safety and Efficacy of HG004 (AAV9-hRPE65) for the Treatment of Inherited Retinal Disease Caused by RPE65 Mutations: A First-in-Human Clinical Trial. 2024. Available from: https:\/\/abstracts.euretina.org\/2024\/lb24-107-9143\/r\/recXxmfDtCMn5RmKI"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.06.035"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01447-8"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017350"},{"key":"e_1_3_5_76_2","unstructured":"Blindness FF. Atsena\u2019s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan. 2024. Available from: https:\/\/www.fightingblindness.org\/news\/atsena-s-lca1-gene-therapy-licensed-by-nippon-shinyaku-for-markets-in-us-and-japan-1465"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309915"},{"key":"e_1_3_5_78_2","unstructured":"Editas. Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1\/2 BRILLIANCE Trial. 2022. Available from: https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-clinical-data-demonstrating-proof"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041327-200020030-00006"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.11.026"},{"key":"e_1_3_5_81_2","unstructured":"Biologics G. Sustained Efficacy and Safety of Bilateral LUMEVOQ\u00ae Injections Four Years After One-Time Administration. 2024. Available from: https:\/\/www.gensight-biologics.com\/2024\/03\/20\/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-four-years-after-one-time-administration\/"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.02.023"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep21587"},{"key":"e_1_3_5_84_2","unstructured":"Neurophth. First patient dosed in Phase III clinical trial for the gene therapy treatment of LHON. 2022. Available from: https:\/\/www.neurophth.com\/en\/NewsD-358.html"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000364"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.08.023"},{"key":"e_1_3_5_87_2","unstructured":"SparingVision. SparingVision Reports Progress on SPVN06 2024. Available from: https:\/\/sparingvision.com\/sparingvision-reports-progress-on-spvn06-at-major-ophthalmology-conferences-2\/"},{"key":"e_1_3_5_88_2","unstructured":"Ocugen. Ocugen Announces Positive Clinical Study Update from the Phase 1\/2 Trial of OCU400 a Modifier Gene Therapy Product Candidate for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA). 2023. Available from: https:\/\/ir.ocugen.com\/news-releases\/news-release-details\/ocugen-announces-positive-clinical-study-update-phase-12-trial"},{"key":"e_1_3_5_89_2","unstructured":"Ocugen. Ocugen Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial\u2014First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication. 2024. Available from: https:\/\/ir.ocugen.com\/news-releases\/news-release-details\/ocugen-inc-announces-us-fda-clearance-ind-amendment-initiate\/"},{"key":"e_1_3_5_90_2","unstructured":"Biologics G. 1 Year Safety data and Efficacy signals from PIONEER Phase I\/II Clinical Trial of GS030 an Optogenetic Treatment Candidate for Retinitis Pigmentosa. 2023. Available from: https:\/\/www.gensight-biologics.com\/2023\/02\/13\/gensight-biologics-announces-1-year-safety-data-and-efficacy-signals-from-pioneer-phase-i-ii-clinical-trial-of-gs030-an-optogenetic-treatment-candidate-for-retinitis-pigmentosa\/"},{"key":"e_1_3_5_91_2","unstructured":"Biologics G. Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment. 2021. Available from: https:\/\/www.gensight-biologics.com\/2021\/11\/17\/gensight-biologics-reports-second-patient-case-showing-significant-visual-recovery-after-gs030-optogenetic-treatment\/"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01351-4"},{"key":"e_1_3_5_93_2","unstructured":"BionicSight. Meaningful Vision Improvements for RP Patients Receiving Highest Dose of its Emerging Optogenetic Therapy. 2023. Available from: https:\/\/www.fightingblindness.org\/news\/bionic-sight-reports-meaningful-vision-improvements-for-rp-patients-receiving-highest-dose-of-its-emerging-optogenetic-therapy-860"},{"key":"e_1_3_5_94_2","unstructured":"Nanoscope. Positive 2-Year Randomized Controlled Trial Results of MCO-010 for Retinitis Pigmentosa. 2024. Available from: https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/"},{"key":"e_1_3_5_95_2","unstructured":"Nanoscope. Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa. 2024. Available from: https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-04016-1"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00310-6"},{"key":"e_1_3_5_98_2","unstructured":"Pitcher JD. Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Neovascular AMD: Results from the Phase II AAVIATE\u00ae Study. 2024. Available from: https:\/\/www.regenxbio.com\/getattachment\/09eea7b5-fa2a-4474-90e2-19d8670a6f6f\/ABBV-RGX-314-SCSwAMD-AAVIATE_Pitcher_RHE2024_FINAL_approved-(1).pdf?lang=en-US&ext=.pdf"},{"key":"e_1_3_5_99_2","unstructured":"4DMT. 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day. 2024. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102394"},{"key":"e_1_3_5_101_2","unstructured":"Adverum. Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results and Provides Key Pivotal Program Design Elements. 2024. Available from: https:\/\/investors.adverum.com\/press_releases\/news-details\/2024\/Adverum-Biotechnologies-Announces-Positive-52-Week-LUNA-and-4-Year-OPTIC-Results-and-Provides-Key-Pivotal-Program-Design-Elements\/default.aspx"},{"key":"e_1_3_5_102_2","unstructured":"Barakat M. Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: 26-Week Interim Analysis Results from the Phase 2 LUNA Study 2024. Available from: https:\/\/adverum.com\/wp-content\/uploads\/Barakat_Ixoberogene-Soroparvovec-Ixo-vec-IVT-Gene-Therapy-2024_09_13.pdf"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.06.013"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178296"},{"key":"e_1_3_5_105_2","unstructured":"Ocugen. Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1\/2 ArMaDa Clinical Trial of OCU410. 2024. Available from: https:\/\/ir.ocugen.com\/node\/13066\/pdf"},{"key":"e_1_3_5_106_2","unstructured":"Ocugen. Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. 2024. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/12\/19\/2999700\/0\/en\/Data-and-Safety-Monitoring-Board-Reviews-Interim-Safety-Data-of-Phase-2-Subjects-of-OCU410-ArMaDa-Clinical-Trial-for-Geographic-Atrophy-Secondary-to-Dry-Age-Related-Macular-Degener.html"},{"key":"e_1_3_5_107_2","unstructured":"4DMT. 4D-150 Wet AMD. 2024. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/static-files\/de51e95a-d81d-45f5-871d-e592fe3b2bda"},{"key":"e_1_3_5_108_2","unstructured":"Therapeutics A. 4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update. 2025. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-presents-positive-60-week-results-4d-150-spectra-clinical"},{"key":"e_1_3_5_109_2","unstructured":"Adverum. Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema. 2021. Available from: https:\/\/www.globenewswire.com\/en\/news-release\/2021\/07\/22\/2267699\/32452\/en\/Adverum-Provides-Update-on-ADVM-022-and-the-INFINITY-Trial-in-Patients-with-Diabetic-Macular-Edema.html"},{"key":"e_1_3_5_110_2","unstructured":"RegenxBio. One Year Data from Phase II ALTITUDE\u00ae Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery. 2023. Available from: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-presents-positive-one-year-data-phase-ii-altituder"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10430342251379824","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10430342251379824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10430342251379824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:50:46Z","timestamp":1777449046000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10430342251379824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":109,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10430342251379824"],"URL":"https:\/\/doi.org\/10.1177\/10430342251379824","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}